Prediction of Rhizoma Drynariae Targets in the Treatment of Osteoarthritis Based on Network Pharmacology and Experimental Verification

Figure 10

p-AKT levels in IL-1β-treated SW1353 cells pretreated with the aqueous extract of Rhizoma Drynariae (AERD) or luteolin. SW1353 cells were pretreated with 2500 mg/L AERD or 30 μmol/L luteolin for 1 h and then treated with 10 ng/mL IL-1β for 12 h. p-AKT (Ser473)/AKT levels were measured by western blotting. The data are derived from three independent experiments and expressed as mean ± standard deviation ( < 0.05: increased when compared with the control group;  < 0.05: decreased when compared with the IL-1β-treated group; and  < 0.05: decreased when compared with the AERD-treated group).

(a)

(b)